Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer

Phase 2TerminatedNCT01333852

Lucas Vieira dos Santos45 enrolled

Overview

Metformin plus paclitaxel for recurrent or metastatic head and neck cancer: a randomized phase II trial

METTAX is a phase II randomized trial that aim to evaluate the addition of metformin to paclitaxel in patients that failed to curative-intent treatment for Head-and neck neoplasms. Patients eligible for this protocol will be randomized to paclitaxel 175mg/m2 plus metformin or placebo until disease progression or unacceptable toxicity. The primary end-point is disease control (complete response, partial response or stable disease, according to RECIST 1.1) in the 12th week. Secondary end-points are PFS, OS, response rate and safety. Molecular markers in samples collected before and under treatment will be tested for correlation with clinical outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Head and Neck Neoplasms Squamous Cell Carcinoma

Interventions

metformin up to 2500mg/dDRUG

metformin up to 2500mg/d

paclitaxel 175mg/m² q21dDRUG

paclitaxel 175mg/m² q21d

placeboDRUG

placebo

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older * Biopsy-proven head and neck squamous cell carcinoma * Ineligibility for curative intent therapy, e.g., surgery or radiation therapy * recurrent or stage IV disease * previous failure to platinum-based chemotherapy * measurable disease according to RECIST v1.1 * PS ECOG 0-2 Exclusion Criteria: * known hypersensitivity to metformin or paclitaxel * SNC metastasis * Acute or chronic infection

Locations (1)

Barretos Cancer Hospital

Barretos, São Paulo, Brazil

Outcomes

Primary Outcomes

Disease control at week 12

Number of subjects at week 12 with complete response, partial response or stable disease, over the total number of subjects, for each arm. Disease control means complete response, partial response or stable disease, according to RECIST 1.1.

Time frame: 12th week

Secondary Outcomes

Progression-free survival

We will measure the number of subjects without progressive disease (complete response, partial response or stable disease) 6mo after the start of therapy, also after 1 and 2 years from the start of therapy. PFS will also be analysed with log-rank test, and reported as HR with respective 95% CI and p value, and median PFS will be estimated with kaplan-meyer method. All calculations will be performed 6 months after the last patient recruited. Also, the survival rate at year one and two will be calculated.

Time frame: 6mo after the last patient recruited

Overall Survival (subjects without death (any cause))

We will measure the number of subjects without death (any cause) 6mo after the start of therapy, and also after 1 and 2 years from the start of therapy. OS will also be analysed with log-rank test, and reported as HR with respective 95% CI and p value, and median OS will be estimated with kaplan-meyer method. All calculations will be performed 6 months after the last patient recruited. Also, the survival rate at year one and two will be calculated.

Time frame: 6mo after the last enrolled patient

Number of patients with Grade 3-5 Adverse Events in each arm, for each category of AE

Safety and tolerability will be assessed using NCI CTCAE v3. The number of patients in each arm experiencing grade 3-5 AE (for each AE) over the total number of subjects will be measured, and the proportion of patients experiencing AE in each arm will be compared using uncorrected chi-sq test. AE will be recorded in baseline and in each visit, and the worst grade AE will be considered.

Time frame: 6 mo after the last enrolled patients

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.